Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christopher E Brightling

Showing results (211-220 of 254) with videos related to

Pageof 26
Sort By:
Respirology (Carlton, Vic.)|October 20, 2021
Global Initiative for Asthma Strategy 2021: Executive Summary and Rationale for Key ChangesHelen K Reddel, Leonard B Bacharier, Eric D Bateman, et al.
Archivos De Bronconeumologia|March 4, 2022
Global Initiative for Asthma Strategy 2021. Executive Summary and Rationale for Key ChangesHelen K Reddel, Leonard B Bacharier, Eric D Bateman, et al.
Lancet (London, England)|May 18, 2026
Safety and efficacy of astegolimab for COPD with frequent exacerbations regardless of baseline blood eosinophil counts (ALIENTO and ARNASA): randomised, double-blind, placebo-controlled, phase 2b and 3 trialsAlberto Papi, Neil J Greening, Surya P Bhatt, et al.
Scientific Reports|December 29, 2019
High degree of polyclonality hinders somatic mutation calling in lung brush samples of COPD cases and controlsGian-Andri Thun, Sophia Derdak, Francesc Castro-Giner, et al.
Chest|February 1, 2026
Sex does not modify prediction of asthma attacks by clinical risk factors and Type-2 biomarkersSebastian Riemann, Fleur L Meulmeester, Samuel Mailhot-Larouche, et al.
The European Respiratory Journal|September 25, 2021
Factors affecting adherence with treatment advice in a clinical trial of patients with severe asthmaJohn Busby, John G Matthews, Rekha Chaudhuri, et al.
The Lancet. Respiratory Medicine|November 28, 2025
Multidimensional prognostic risk stratification of COPD exacerbations: the baseline, acuity, and trigger (BAt) modelHnin W W Aung, Kristina Vermeersch, Hamish J C McAuley, et al.
Trials|January 6, 2018
A randomised pragmatic trial of corticosteroid optimization in severe asthma using a composite biomarker algorithm to adjust corticosteroid dose versus standard care: study protocol for a randomised trialCatherine E Hanratty, John G Matthews, Joseph R Arron, et al.
Wellcome Open Research|December 13, 2024
Extended Cohort for E-health, Environment and DNA (EXCEED) COVID-19 focusPaul H Lee, Anna L Guyatt, Catherine John, et al.
The Lancet. Respiratory Medicine|September 11, 2020
Composite type-2 biomarker strategy versus a symptom-risk-based algorithm to adjust corticosteroid dose in patients with severe asthma: a multicentre, single-blind, parallel group, randomised controlled trialLiam G Heaney, John Busby, Catherine E Hanratty, et al.
Pageof 26

Showing results (211-220 of 254) with videos related to

Sort By:
Pageof 26
Respirology (Carlton, Vic.)|October 20, 2021
Global Initiative for Asthma Strategy 2021: Executive Summary and Rationale for Key ChangesHelen K Reddel, Leonard B Bacharier, Eric D Bateman, et al.
Archivos De Bronconeumologia|March 4, 2022
Global Initiative for Asthma Strategy 2021. Executive Summary and Rationale for Key ChangesHelen K Reddel, Leonard B Bacharier, Eric D Bateman, et al.
Lancet (London, England)|May 18, 2026
Safety and efficacy of astegolimab for COPD with frequent exacerbations regardless of baseline blood eosinophil counts (ALIENTO and ARNASA): randomised, double-blind, placebo-controlled, phase 2b and 3 trialsAlberto Papi, Neil J Greening, Surya P Bhatt, et al.
Scientific Reports|December 29, 2019
High degree of polyclonality hinders somatic mutation calling in lung brush samples of COPD cases and controlsGian-Andri Thun, Sophia Derdak, Francesc Castro-Giner, et al.
Chest|February 1, 2026
Sex does not modify prediction of asthma attacks by clinical risk factors and Type-2 biomarkersSebastian Riemann, Fleur L Meulmeester, Samuel Mailhot-Larouche, et al.
The European Respiratory Journal|September 25, 2021
Factors affecting adherence with treatment advice in a clinical trial of patients with severe asthmaJohn Busby, John G Matthews, Rekha Chaudhuri, et al.
The Lancet. Respiratory Medicine|November 28, 2025
Multidimensional prognostic risk stratification of COPD exacerbations: the baseline, acuity, and trigger (BAt) modelHnin W W Aung, Kristina Vermeersch, Hamish J C McAuley, et al.
Trials|January 6, 2018
A randomised pragmatic trial of corticosteroid optimization in severe asthma using a composite biomarker algorithm to adjust corticosteroid dose versus standard care: study protocol for a randomised trialCatherine E Hanratty, John G Matthews, Joseph R Arron, et al.
Wellcome Open Research|December 13, 2024
Extended Cohort for E-health, Environment and DNA (EXCEED) COVID-19 focusPaul H Lee, Anna L Guyatt, Catherine John, et al.
The Lancet. Respiratory Medicine|September 11, 2020
Composite type-2 biomarker strategy versus a symptom-risk-based algorithm to adjust corticosteroid dose in patients with severe asthma: a multicentre, single-blind, parallel group, randomised controlled trialLiam G Heaney, John Busby, Catherine E Hanratty, et al.
Pageof 26